Atrial Fibrillation Clinical Trial
Official title:
Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery
In this study, the investigators aim to determine whether injecting botulinum toxin into epicardial fat pads is efficacious and safe for decreasing postoperative atrial fibrillation (POAF) after cardiac surgery. The investigators will test the hypothesis that botulinum toxin injected into the epicardial fat pads reduces POAF and length of stay (LOS) without increasing adverse events. This will be a prospective randomized trial of 130 patients undergoing coronary artery bypass graft (CABG), valve surgery or CABG + valve surgery with cardiopulmonary bypass. Patients will be randomized to receive either botulinum toxin (50 units per fat pad, n=65) or normal saline/placebo (1 mL per fat pad, n=65) injected into epicardial fat pads. All patients will receive standardized anesthetic, surgical, and post-surgical care. The primary outcome in this study will be time to occurrence of in-hospital POAF. Based on previous work and a pilot trial showing a pronounced reduction (relative risk reduction 77%) in POAF after injecting botulinum into the epicardial fat pads, the investigators anticipate a significant reduction in the risk for POAF with epicardial botulinum in this cohort, which includes valve surgery patients.
Purpose of the study: A pilot study to determine whether injecting botulinum toxin into
epicardial fat pads is efficacious and safe for decreasing postoperative atrial fibrillation
(POAF) after cardiac surgery
Hypothesis to be tested: Botulinum toxin injected into the epicardial fat pads reduces POAF.
Design and Procedures: This will be a prospective randomized pilot trial of 130 patients
undergoing coronary artery bypass graft (CABG), valve surgery or CABG + valve surgery via
median sternotomy with cardiopulmonary bypass. Patients <50 years of age, with chronic atrial
fibrillation, prior cardiac surgery, EF<25%, preoperative inotropic support, hepatic or renal
failure, known sensitivity to botulinum toxin, debilitating neuromuscular disease, or those
with a history of atrioventricular block will be excluded from the study. Prior to surgery,
all patients will have baseline Mini-Mental State Examination (MMSE) and blood sampling from
an indwelling arterial line or venipuncture for measurement of inflammatory and genomic
markers. Half of the patients will be randomized to receive injection of epicardial botulinum
toxin in addition to standard of care, as described below. The other half will receive
epicardial injection of normal saline.
Institution of cardiopulmonary bypass will be performed according to the routine surgical
protocol. After instituting CPB, botulinum toxin (or normal saline) injections will be
performed by the surgeon. This dose was selected given the prior report of its effectiveness
in preventing POAF after cardiac surgery in a small pilot study.(Pokushalov et al., 2014)
After completion of surgery and separation from CPB, patients will proceed along the
institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG
(telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and
will be defined as new-onset if it occurs postoperatively at any time before hospital
discharge. POAF, if it occurs, will be treated as per routine of care. POAF will be defined
as any detectable atrial fibrillation before discharge that lasts >30 seconds. On
postoperative day (POD) 4, a member of the study team will visit each patient to administer
the MMSE and capture a 5-minute ECG with a Holter monitor. In addition, patients will be
contacted monthly for 4 months and at one year after surgery for follow up, and medical
records will be reviewed for evidence of readmissions, arrhythmias, or other adverse events.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |